Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update

Lexicon Pharmaceuticals (Nasdaq:LXRX), today reported financial results for the three months and full-year ended December 31, 2017 and highlighted progress with the company’s commercial product, XERMELO^® (telotristat ethyl), its pipeline drug candidates and its overall business. The company will conduct a conference call and webcast today at 8:00 am EST / 7:00 am CST to discuss the financial results and to provide a business update.

As quoted in the press release:

“We enter 2018 with a well-defined strategy to position the company for future growth and to build long-term sustainable value for shareholders,” continued Mr. Coats. “XERMELO remains a significant franchise for us, and we are extremely excited about exploring the use of telotristat ethyl in additional therapeutic indications where the role of serotonin inhibition has shown preclinical promise. In parallel, we and Sanofi look forward to filing for regulatory approval in the U.S. and in Europe for sotagliflozin in type 1 diabetes in the upcoming weeks. Lastly, we continue to advance our earlier-stage product candidates in areas we believe will create long-term value for the company.”

Click here to read the full press release.